When developing a new drug product, quality, safety and timing are critical. A Contract Development and Manufacturing Organization (CDMO) can be a valuable partner to help mitigate risks, avoid missteps and control costs in the process. But the success of the partnership revolves around a key step: the technology transfer.
Cell and gene therapies offer new opportunities for the development of potentially life-saving treatments for previously incurable diseases. This eBook informs on bioprocess solutions to support novel drug development.
This note demonstrates identification of Infliximab charge variants from intact mass analysis enabled by two-dimensional liquid chromatography
Vetting contract fill finish manufacturers is about more than their capacity. Jubilant HollisterStier advises on what to look for in a sterile fill finish partner.
Is software critical to your success with Multiple-Attribute Methods? Hear from experts across the industry in volume 5 of our Expert Discussion Series. Learn about their perspectives on informatics requirements for MAM.
Hear from experts across the industry in volume 1 of our Expert Discussion Series on Multi Attribute Methods. Learn about their perspectives on the opportunities and challenges of implementing MAM in their lab.
How confident are you deploying LC-MS systems for Multi-Attribute Methods in routine labs? Hear from experts across the industry in volume 6 of our Expert Discussion Series on Multi-Attribute Methods. Learn about their perspectives on system requirements for MAM.
Download this eBook for fresh perspectives on the capabilities and adoption of MAM workflows within the biopharmaceutical industry.
How to handle new peak detection with Multi-Attribute Methods? Hear from experts across the industry in volume 3 of our Expert Discussion Series. Learn about their perspectives on the considerations of new peak detection
Download this application notebook illustrating key attribute monitoring workflows developed to improve and streamline MAM analysis of biotherapeutic proteins.
Can you really deploy a Multiple-Attribute Method in a routine lab? Hear from experts across the industry in volume 4 of our Expert Discussion Series.
Hear from experts across the industry in volume 2 of our Expert Discussion Series on Multi Attribute Methods. Learn about their perspectives on MAM sample preparation and automation.
Designed for advanced therapy manufacturing, the Marlborough, MA facility is the first new construction at Resilience. The site will produce, rest, and release viral vector drug substance (DS) and drug product (DP), for clinical and commercial use.
When it comes to viral vectors, the complexities related to varying serotypes and different sized payloads continue to impact efficiencies and timelines. Hear from Resilience experts on how innovative platform technologies can overcome these challenges and support scalable manufacturing.
There are many reasons behind the success of a technology transfer. But at the center of this complexity is one critical role: project management in the tech transfer.
Sterile filtration is essential within many steps of a bioprocessing operation, both upstream and downstream, ensuring the biopharmaceutical product’s proper performance, safety, and quality. When seeking to maximize filtration efficiency, it helps to understand how sterile filtration and single-use systems work together, as well as how optimizing the filter design for specific applications can enhance performance.
When developing a new drug product, quality, safety and timing are critical. A Contract Development and Manufacturing Organization (CDMO) can be a valuable partner to help mitigate risks, avoid missteps and control costs in the process. But the success of the partnership revolves around a key step: the technology transfer.
Conventional freezer technology may take hours to days to recover to a -80°C set point after a door opening, leaving valuable drug product/drug substance at risk and compromising sample integrity. Watch as the FARRAR ULC Series recovers from a 30-second door opening back to -80°C in under 20 minutes.
The need for -60°C through -80°C assets to help future-proof manufacturing facilities has increased significantly over the past decade - clinical research investments have expanded while commercial-scale needs continue to transform the landscape. Cold wall remains the gold standard due to a lack of alternative solutions. Several factors, however, have placed stress on cold-wall technologies to perform in applications for which they were not designed or intended.
Grand River Aseptic Manufacturing (“GRAM”) needed commercial-scale, ultra-low temperature capacity units at -50°C delivered immediately to store forthcoming raw materials. A typical timeline for these solutions can run months, which did not meet GRAM’s needs. Working with FARRAR and creating cross-company project team enabled a typically long delivery cycle to be completed quickly and safely, with storage beginning 18 business days after the initial call (including a national holiday). Matthew Van Gessel, Senior Manager of Capital Projects and Expansion at GRAM, stated, “In a matter of weeks, the FARRAR and GRAM teams went from placing the order to installation, qualification, release, and use of the -50°C freezers. The strength in partnership and culmination of responsive communication and coordination between the two teams resulted in the expedited outcome.
The biotechnology industry is both vast and complex, with sectors varying from agricultural to pharmaceutical. Regardless of the sector, the goal remains the same – benefiting society through the creation of pharmaceutical, diagnostic, agricultural, environmental, and other products that utilize living cells and cellular materials. These products demand the development of innovative bioprocessing techniques as well as advanced equipment that can support each stage in the flow. Check out this technical article to learn more about ultra-low temperature considerations for bioprocessing.
The significant growth of the biologic drug market, bolstered by the COVID-19 pandemic and the development of relevant vaccines, along with the growing complexity and fragility of biologic drugs, has led to a need for improved freezing and thawing methods. While biologic drugs are becoming more mainstream as the pharmaceutical industry focuses on their development, maintaining high yields becomes critical to enabling timely introduction to the market and ensuring sufficient supplies. New technology exists that can help ensure higher yields and help meet demand timelines. Check out this white paper to learn more.
To help customers leverage digital transformation and prepare for the lab of the future, LabVantage Solutions has devised a five-step process for successfully implementing and profiting from AI in the lab and across the enterprise.
A subscription-based LIMS, hosted in the cloud and delivered via internet, is a proven secure, scalable, and cost-effective alternative to traditional software licensing, installation, maintenance, validation, and management. Learn all the benefits of a SaaS delivery model for modern lab informatics solutions.
In this white paper, learn how to drive growth by establishing integrated, AI-fueled lab systems and a data-driven corporate culture that’s ready and resilient, no matter what business challenges emerge tomorrow.
Digital transformation is about more than moving from paper to glass. It’s about the way that enterprises use technology and data to build a business ecosystem, thereby reducing risk, accelerating innovation, and driving growth.
Non-infectious mock virus particles that mimic the physicochemical properties of live infectious viruses can be used as spiking agents during viral clearance testing.
Intensified continuous chromatography, a type of Multi-Column Chromatography (MCC), has emerged as a valuable technique in downstream bioprocessing that enables increases in productivity. In this podcast, MCC Product Specialist, Jennifer Knister, will discuss how adopting MCC can reduce costs, decrease suite time, and lead to higher resin utilization, along with why these benefits are particularly worthwhile in multi-product facilities.
This research outlines recent changes in the monoclonal antibody market, the great potential for pathogen-focused mAb treatments and important industry factors impacting how to antibody products can navigate through clinical stages.
